In the past few years, drug-discovery researchers have become increasingly interested in covalent inhibitors — compounds that bind and inhibit a target protein by forming a covalent bond to it 1, 2, ...

Tango Therapeutics Inc. has disclosed the discovery of TNG-348, an orally active, potent, reversible allosteric inhibitor of the USP1 deubiquitinating enzyme.

Jaypirca, the first and only FDA-approved non-covalent (reversible) BTK inhibitor, is a highly selective kinase inhibitor that utilizes a novel non-covalent binding mechanism to extend the benefit of ...

Mantle cell lymphoma (MCL) relapsed or refractory in patients who have previously received at least two lines of systemic therapy including a Bruton tyrosine kinase (BTK) inhibitor; or Chronic ...

(PHILADELPHIA) – Combining natural organic atoms with metal complexes, scientists at The Wistar Institute have developed a new type of enzyme inhibitor capable of blocking a biochemical pathway that ...

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are antihypertensive medicines used to treat high blood pressure. While the enzyme inhibitors work by reducing the level of ...

Using computational tools and virtual screening, researchers at the Center for Redox Processes in Biomedicine (Redoxoma) have ...

Cardiovascular illnesses, such as high blood pressure and heart problems, are often treated with angiotensin-converting enzyme (ACE) inhibitors. The ACE inhibitors lower blood pressure by relaxing ...

Approval is based on results from the BRUIN CLL-321 trial, the only randomized Phase 3 study in CLL/SLL in which all patients were previously treated with a covalent BTK inhibitor This expanded ...